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DMBA/TPA Treatment Is Necessary for BCC
Formation from Patched Deficient Epidermal
Cells in Ptchflox/floxCD4Creþ / Mice
Anja Uhmann1, Ina He1, Anke Frommhold1, Simone Ko¨nig1, Sebastian Zabel1, Frauke Nitzki1, Kai Dittmann2,
Fred Lu¨hder3, Hans Christiansen4, Julia Reifenberger5, Walter Schulz-Schaeffer6 and Heidi Hahn1
The development of basal cell carcinoma (BCC), the most frequently diagnosed tumor among persons with
European ancestry, is closely linked to mutations in the Hedgehog (Hh) receptor and tumor suppressor Patched1
(Ptch). Using Ptchflox/floxCD4Creþ / mice, in which Ptch was ablated in CD4Cre-expressing cells, we demonstrate
that the targeted cells can give rise to BCC after treatment with DMBA (7,12-dimethylbenz(a)anthracene)/TPA
(12-O-tetradecanoylphorbol-13-acetate), but not after wounding of the skin. In addition, in this model, BCC are
not caused by malfunctioning of Ptch-deficient T cells, as BCC did not develop when bone marrow (BM) of
Ptchflox/floxCD4Creþ / mice was transplanted into Ptch wild-type mice. Instead, lineage-tracing experiments and
flow cytometric analyses suggest that the tumors are initiated from rare Ptch-deficient stem cell-like cells of the
epidermis that express CD4. As DMBA/TPA is a prerequisite for BCC development in this model, the initiated cells
need a second stimulus for expansion and tumor formation. However, in contrast to papilloma, this stimulus
seems to be unrelated to alterations in the Ras signaling cascade. Together, these data suggest that biallelic loss of
Ptch in CD4þ cells does not suffice for BCC formation and that BCC formation requires a second so far unknown
event, at least in the Ptchflox/floxCD4Creþ / BCC mouse model.
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INTRODUCTION
The Hh receptor and tumor suppressor Ptch is thought to act
as a ‘gate keeper’ for the development of BCC, which is the
most common skin tumor. Indeed, biallelic Ptch mutations
are thought to suffice for BCC formation (Adolphe et al.,
2006). Inactivation of Ptch suspends the inhibition of
Smoothened (Smo) and triggers the activation of the Hh
signaling pathway. In BCC, activation of the Hh pathway
can be reliably monitored by the overexpression of the Hh
target genes Gli1 and Ptch itself, the latter thus being
regulated in a negative feedback (Dahmane et al., 1997; for
review see Epstein, 2008).
In the skin, multipotent stem cells are found in the bulge
region of the hair follicle and in the interfollicular epidermis.
These stem cells are normally responsible for hair follicle
regeneration and epidermal repair during wound healing,
respectively. They can also give rise to skin cancer
(Blanpain et al., 2004; Morris et al., 2004; Tumbar et al.,
2004; Ito et al., 2005; Levy et al., 2005; Levy et al., 2007).
Until now, the cellular origin of BCC is thought to be a stem
cell localized in the hair follicle, the interfollicular epidermis,
or in the reservoir of follicular stem cells (Youssef et al., 2010;
Kasper et al., 2011; Wong and Reiter, 2011). However,
there is evidence that BM cells could be a source of
BCC as well. This is based on the observation that BM
cells can transdifferentiate into keratinocytes and integrate
into the basal layer and hair follicle (Borue et al.,
2004; Inokuma et al., 2006). In addition, transplanted GFP-
expressing murine BM cells appear 4 weeks after engraftment
as keratinocyte marker-positive BM cells in the epidermis, hair
follicles, and sebaceous glands (see review Oyama and
Kaneko, 2011).
To investigate the function of Ptch in T cells, we previously
crossed Ptchflox/flox to CD4Cre transgenic mice. The latter
strain expresses the Cre recombinase under control of
the murine CD4 promoter/enhancer/silencer (Sawada et al.,
1994). As expression of this transgene beyond CD4-expressing
immune cells has not been described yet, CD4Cre mice are
extensively used for investigation of conditional T cell-specific
gene knockout (e.g., Lee et al., 2001; Wolfer et al., 2001;
Christie et al., 2012; Tai et al. 2013).
The data from Ptchflox/floxCD4Creþ / mice showed that the
T cell-specific Ptch mutation does not interfere with T-cell
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development (Uhmann et al., 2011). It also does not com-
promise the function of T cells (Michel et al., 2013). Indeed,
Ptchflox/floxCD4Creþ / mice are healthy and are neither prone
to infection nor to spontaneous tumor development.
Here we tested the susceptibility of Ptchflox/floxCD4Creþ /
mice to chemically induced tumor formation using the two-
stage chemical carcinogenesis DMBA/TPA protocol. Follow-
ing this protocol, skin tumors are initiated by a single exposure
to DMBA and are promoted by repeated application of the
inflammation-inducing TPA. In general, DMBA/TPA treatment
results in the development of premalignant papilloma, squa-
mous cell carcinoma (DiGiovanni, 1992), and nevi (Sotillo
et al., 2001). In contrast, BCC are not observed in DMBA/
TPA-treated wild-type mice (Indra et al., 2007). We show
that besides papilloma all DMBA/TPA-treated Ptchflox/flox
CD4Creþ / mice develop BCC, in which both Ptch alleles
are lost. Restriction fragment length polymorphism (RFLP)
analyses and immunohistological stainings revealed that
the BCC neither harbor the common DMBA-induced Hras
G61L mutation nor exhibit active Ras signaling. However,
BM transplantation, lineage-tracing experiments, and flow
cytometric analyses indicate that the BCC are supposedly
derived from, to our knowledge previously unreported, rare
CD4-expressing stem cell-like population of the murine skin.
Finally, and most importantly, our data support a model in
which the expansion of a Ptch mutant BCC precursor cell by
an inductive trigger is a necessary event for BCC formation.
RESULTS
DMBA/TPA treatment, but not wounding, induces BCC in
Ptchflox/floxCD4Creþ / mice
Ptchflox/floxCD4Creþ / and Ptchflox/floxCD4Creþ /R26RT/
mice were subjected to the two-stage DMBA/TPA carcinogen-
esis protocol, as described in the Materials and Methods
section. The latter mouse line was generated to perform
lineage-tracing experiments. In Ptchflox/floxCD4Creþ /
R26RT/ mice, all progeny of CD4Cre-expressing cells are
marked by permanent expression of b-galactosidase (LacZ).
Twenty-six or 34 weeks after onset of treatment, the mice were
killed and the skin was removed for analysis (see
Supplementary Table S1 online).
The weekly examination of the Ptchflox/floxCD4Creþ / and
Ptchflox/floxCD4Creþ /R26RT/ mice revealed that neither
the latency time nor the numbers (Supplementary Figure
S1a, c, and d online and Supplementary Figure S7a online)
and size (Supplementary Figure S1b online) of papillomas
differ in comparison with control mice. Similarly, the numbers
of melanoma-like nevi that were observed in all DMBA/TPA-
treated mice showed no significant differences (Supplementary
Figure S7b online). However, the DMBA/TPA treatment led to
the development of BCC in 100% Ptchflox/floxCD4Cre and
Ptchflox/floxCD4Creþ /R26RT/ mice examined. In contrast,
BCC were never detected in the DMBA/TPA-treated controls
(Supplementary Figure S1c and d online) or in untreated
Ptchflox/floxCD4Cre and Ptchflox/floxCD4Creþ /R26RT/ mice.
In addition, BCC only developed at the site of DMBA/TPA
treatment but not at untreated areas of Ptchflox/floxCD4Creþ /
mice. The tumors were small and visible only by microscopy.
In addition, all BCC were similar with respect to histology
(Supplementary Figure S2 online). Frequencies of developing
papilloma or papilloma (for histological differentiation see
Supplementary Figure S1 online) did not differ between
Ptchflox/floxCD4Creþ / and Ptchflox/flox mice. Furthermore,
we did not observe a correlation between papilloma and
BCC development in Ptchflox/floxCD4Creþ / mice (Supple-
mentary Figure S1c and d online).
Immunohistological stainings against CD3, which is a co-
receptor of the T-cell receptor and is expressed on CD4þ T
cells (CD4 immunohistochemical analysis was not possible in
our hands), demonstrated that CD3þ cells were located in the
dermis and the basal layer of the epidermis of both DMBA/
TPA-treated and untreated skin from Ptchflox/floxCD4Creþ /
mice (Figure 1a and b, respectively). Nevertheless, DMBA/
TPA treatment led to a higher T-cell infiltration in the dermis
and to CD3þ infiltrates of the suprabasal layer of the stratum
spinosum (Supplementary Figure S3a and b online; Darwiche
et al., 2007) and of BCC (Figure 1a). However, the BCC cells
themselves were not positive for this T-cell marker (Figure 1a).
We also analyzed the Hh signaling activity in BCC by in situ
hybridization. First, the sections were stained with two
different Ptch probes. Although the 250-bp probe exclusively
detects the wt Ptch mRNA transcribed from the Ptchflox locus,
the 477-bp probe detects Ptch transcripts derived from both
the mutant Ptch (Ptchdel) and the Ptchflox locus (Wijgerde
et al., 2005; Zibat et al., 2009). As shown in Figure 1c, BCC
stained positive with the 477-bp probe, whereas no signals
were detected when using the 250-bp probe (Figure 1e; see
Figure 1d for wt Ptch expression in the hair follicles that served
as internal positive controls). These data clearly demonstrate
that both Ptchflox alleles were efficiently recombinated and
that wt Ptch is lost in BCC cells. As a result, the mutant Ptch
transcripts were overexpressed in BCC.
The sections were also stained with an in situ probe to
detect the Hh marker Gli1. As shown in Figure 1f, Gli1 was
highly expressed in BCC, demonstrating that Hh signaling was
strongly activated in the tumor cells. In contrast to BCC,
papilloma of DMBA/TPA-treated mice never stained positive
for Gli1 (Supplementary Figure S3c and d online; positive
staining of hair follicles are indicated by arrows) or Ptch
(Supplementary Figure S3e and f online).
It has been shown previously that BCC can occur after
wounding in Ptch mutant mice and also in Gli1 and SMO
transgenic animals. In these models, the tumor-promoting
effect of the wound environment is thought to rely on the
recruitment of mutant tumor-initiating stem cells from the hair
follicles to the wound site (Kasper et al., 2011; Wong and
Reiter, 2011). To investigate whether the tumor-promoting
effect in Ptchflox/floxCD4Creþ / mice follows a similar mecha-
nism, we wounded the skin of Ptchflox/floxCD4Creþ /and
Ptchflox/flox control mice by skin incisions at the anagen
(right flank) or telogen (left flank) stages of the hair cycle.
Ten or 20 weeks (see Supplementary Table S1 online) there-
after, the mice were killed and the wound areas were
examined by means of microscopic analysis of hematoxylin-
and eosin-stained paraffin sections. However, similar to the
controls, Ptchflox/floxCD4Creþ / mice did not develop any
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BCC. Together, these data indicate that BCC in Ptchflox/flox
CD4Creþ / are probably not derived from a targeted stem cell
of the hair follicle. Moreover, as BCC were neither detected in
DMBA/TPA-treated Ptchflox/flox nor in vehicle-treated Ptchflox/
floxCD4Creþ / control mice, these results suggest that the Ptch
depletion in conjunction with DMBA/TPA treatment is a
prerequisite for BCC formation in this model.
BCC of Ptchflox/floxCD4Creþ / mice do not show the activating
Hras G61L mutation that is typically found in papilloma of
DMBA/TPA-treated skin
One of the initiating events of experimental mouse skin
carcinogenesis by DMBA/TPA treatment is the mutation of
codon 61 of the Hras gene (Hras G61L; Quintanilla et al.,
1986). This mutation can be detected in over 90% of DMBA/
TPA-induced papilloma and carcinoma (Kemp et al., 1993).
To analyze whether this mutation is also found in DMBA/TPA-
induced BCC of Ptchflox/floxCD4Creþ / mice, genomic DNA
from microdissected BCC tissue of Ptchflox/flox CD4Creþ /
mice (see Supplementary Figure S4 online) was analyzed for
the Hras G61L mutation by RFLP analyses. For this purpose,
exon 2 of the Hras gene was amplified and the amplification
product was digested either with AvaII or XbaI. AvaII digestion
results in a 112-bp and a 96-bp fragment. XbaI does not digest
the wt sequence, whereas digestion of the mutated sequence
(Hras G61L) results in an 88-bp and a 120-bp fragment (see
Supplementary Method section and Supplementary Figure S5
online; Nagase et al., 2003). Genomic DNA derived from
microdissected papilloma of Ptchflox/floxCD4Creþ / and
Ptchflox/flox mice served as controls (see Supplementary Figure
S4 online). Figure 2a shows that DMBA/TPA-induced papil-
loma of either 4/5 Ptchflox/flox CD4Creþ / or 4/5 Ptchflox/flox
mice harbor the Hras G61L mutation. However, the Hras
G61L mutation was never found in BCC of Ptchflox/flox
CD4Creþ / mice (Figure 2a).
As the oncogenic Hras G61L mutation can result in
phosphorylation of the Ras downstream effectors ERK1/2
(extracellular signal–regulated kinases; Chen et al., 2009),
Ras signaling activity of DMBA/TPA-treated skin Ptchflox/flox
CD4Creþ / mice was analyzed by anti-pERK1/2
immunohistological stainings (Figure 2b–d). As expected from
the RFLP data, DMBA/TPA-induced papilloma were strongly
positive for pERK1/2 (Figure 3b and c). However, BCC of
DMBA/TPA-treated Ptchflox/floxCD4Creþ / never stained posi-
tive for pERK1/2 (Figure 3d).
Taken together, these data suggest that the molecular events
that are involved in DMBA/TPA-induced formation of BCC or
papilloma in Ptchflox/floxCD4Creþ / mice are substantially
different.
BCC of Ptchflox/floxCD4Creþ / mice are derived from Ptch-
deficient epidermal cells
The CD4Cre mouse strain is invariably used to conditionally
inactivate genes in T cells of the immune system (e.g., Lee
et al., 2001; Wolfer et al., 2001; Christie et al., 2012; Tai
et al., 2013). Therefore, BCC in Ptchflox/floxCD4Creþ / mice
could have been the result of a generalized immune
deficiency caused by Ptch-deficient T cells. However,
previous work of our group showed that the Ptch deficiency
in T cells does not compromise any immunological function
(Uhmann et al., 2011; Michel et al., 2013). Because of this
observation and as the BCC in DMBA/TPA-treated mice are
derived from a Ptch-deficient cell population (see Figure 1),
we hypothesized that the tumors in our setting originate from
specific CD4-expressing cells localized in the basal layer of
the skin. To test this hypothesis, we performed a lineage-
tracing experiment by visualizing CD4Cre-expressing cells in
Ptchflox/floxCD4Creþ /R26RT/þ mice by means of LacZ
stainings. The investigation of untreated skin from Ptchflox/flox
CD4Creþ /R26RT/þ revealed LacZ-stained cells in the basal
layer of the epidermis and in cells of the root sheath
a
CD3 CD3
mut/wt Ptch wt Ptch
wt Ptch Gli1
b
c d
e f
Figure 1. Histological analyses of DMBA/TPA-induced BCC. Anti-CD3
immunhistological stainings of (a) DMBA/TPA-induced BCC of
Ptchflox/floxCD4Creþ / and (b) untreated control skin. Arrows: dermal CD3þ
cells; dashed arrows: epidermal CD3þ cells in the basal layer; inset:
tumor-infiltrating CD3þ cells. (c–f) In situ hybridizations to visualize the
expression of the Ptch (477 bp probe in c), the wt Ptch (250 bp probe in d
and e), or Gli1 (f) transcripts of DMBA/TPA-induced BCC of Ptchflox/flox
CD4Creþ / skin. Panel d shows wt Ptch expression in the hair follicle (arrows).
For detailed explanation of the 477-bp and 250-bp Ptch probes, see the
main text. Note that a, c, and e are adjacent sections of the same BCC.
Bar ¼ 200mm. BCC, basal cell carcinoma; DMBA, 7,12-
dimethylbenz(a)anthracene; TPA, 12-O-tetradecanoylphorbol-13-acetate.
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(Supplementary Figure S6 online). Some LacZþ cells coex-
pressed the T-cell marker CD3 (marked by double arrows in
Supplementary Figure S6a–d online). These data suggest that
these LacZþ CD3þ double-positive cells were indeed T-cells,
in which CD4 was expressed. However, some cells stained
only positive for LacZ and did not coexpress the T cell-specific
marker CD3 (marked with arrows in Supplementary Figure
S6c–f online). This indicates that these LacZþ cells are
CD4Cre-expressing cells, which are unrelated to T-cell
lineages.
LacZ staining of DMBA/TPA-treated skin from Ptchflox/flox
CD4Creþ /R26RT/þ mice revealed that some BCC were
negative for LacZ (marked by an asterisk in Figure 3a) and
some stained positive for LacZ (Figure 3a, see also
Supplementary Figure S7c online). As all BCC, however, were
negative for CD3 (Figure 1a), this result suggests that BCC are
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Figure 2. RFLP analyses of the Hras G61L mutation and pERK1/2 immunohistological staining of DMBA/TPA-induced BCC and papilloma. (a) Amplification
of Hras exon 2 (upper lane), and subsequent RFLP analyses by AvaII or XbaI digestion (see main text, Supplementary Figure S5 and the Supplementary
Methods section online) of genomic DNA isolated from papilloma of DMBA/TPA-treated Ptchflox/flox mice (pap1-5) and from papilloma and BCC of DMBA/TPA-
treated Ptchflox/floxCD4Creþ / mice (pap1-5 and BCC1-5, respectively). Genomic DNA from a wild-type mouse (wt) or a BCC of a Ptchflox/floxCreERT2þ /mouse
(BCC) (Zibat et al., 2009) served as controls. Asterisks: Hras G61L-positive papilloma. (b–d) Anti-pERK1/2 immunohistological stainings of papilloma
(b and c) and BCC (d) of DMBA/TPA-treated Ptchflox/floxCD4Creþ / mice. Arrows: pERK1/2-positive papilloma; asterisk: BCC. Bar ¼ 200mm. BCC, basal
cell carcinoma; DMBA, 7,12-dimethylbenz(a)anthracene; RFLP, restriction fragment length polymorphism; TPA, 12-O-tetradecanoylphorbol-13-acetate.
LacZ LacZ/Gli1
*
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a b c
Figure 3. LacZ staining and Gli1 in situ hybridization for the Gli1 expression of DMBA/TPA-induced BCC from Ptchflox/floxCD4Creþ /R26RT/þ mice. (a) LacZ-
stained DMBA/TPA-induced BCC of Ptchflox/floxCD4Creþ /R26RT/þ skin. Asterisk: LacZ-negative BCC. (b) Gli1 expression of LacZþ BCC and (c) of LacZ BCC.
Bar ¼ 200mm. BCC, basal cell carcinoma; DMBA, 7,12-dimethylbenz(a)anthracene; LacZ, b-galactosidase; TPA, 12-O-tetradecanoylphorbol-13-acetate.
A Uhmann et al.
Ptch-Dependent BCC Growth upon DMBA/TPA Treatment
www.jidonline.org 2623
not derived from the T-cell lineage. To confirm that activation
of Hh signaling was indeed the BCC-initiating event and that
the lack of LacZ expression in some BCC was only indicative
for a different efficiency of the CD4Cre recombinase at the
R26R and the Ptchflox loci, we analyzed Hh signaling activity
by means of Gli1 in situ hybridization in LacZþ and LacZ
BCC of Ptchflox/floxCD4Creþ /R26RT/þ mice. Indeed, both
LacZþ and LacZ BCC of Ptchflox/floxCD4Creþ /R26RT/þ
skin were strongly positive for Gli1 (Figure 3b and c). These
data suggest that activation of Hh signaling was the BCC-
initiating event. In addition, the data indicate that Ptch was
efficiently deleted in all BCC and that the floxed Ptch locus
was more sensitive to Cre-mediated recombination than the
floxed R26R locus (for differences in Cre sensitivity see
Schmidt-Supprian and Rajewsky, 2007).
Taken together, these results suggest that the BCC of DMBA/
TPA-treated Ptchflox/floxCD4Creþ / mice were derived from
Ptch-deficient CD4þ or CD4Cre-expressing epidermal cells,
which are most likely unrelated to the lymphoid lineage and
to T cells.
BCC of Ptchflox/floxCD4Creþ / mice are not derived from
hematopoietic cells
To validate our hypothesis that the CD4þ or CD4Cre-expres-
sing cells that give rise to BCC after DMBA/TPA treatment
were not derived from the lymphoid lineage of the BM, we
repopulated immune-deficient Rag2 /cyc / mice with
BM of Ptchflox/floxCD4Creþ /R26RT/þ mice (and also of
Ptchflox/floxCD4Creþ / mice; see Supplementary Table S1
online). Successful reconstitution was tested 6 weeks after
transplantation by FACS analyses (see Materials and Methods
section, Supplementary Figure S8a online). Afterward, the
mice were treated with DMBA/TPA. However, although the
transplanted mice developed papilloma, they never developed
BCC. Thus, these data support our hypothesis that BCC of
DMBA/TPA-treated Ptchflox/floxCD4Creþ /mice are not
derived from the lymphoid lineage of the BM (Supple-
mentary Table S2 online). It also underlines our assumption
that BCC are not the result of a generalized immune
deficiency caused by Ptch-deficient immune cells (Uhmann
et al., 2011; Michel et al., 2013).
These conclusions were additionally fostered by another
transplantation experiment, in which BM of GFP transgenic
mice was transplanted into lethally irradiated Ptchflox/flox
CD4Creþ / or Ptchflox/flox control mice (see Supplementary
Table S1 online). Thus, in the transplanted hosts, all cells
derived from the graft can be monitored by GFP expression.
Successful reconstitution of the hosts was tested 6 weeks after
transplantation by FACS analyses of blood cells (see Materials
and Methods section, Supplementary Figure S8b online).
Thereafter, the mice were treated with DMBA/TPA. After 20
weeks, the skin was removed and subjected to hematoxylin
and eosin staining and immunohistochemical analysis.
Besides papilloma, all Ptchflox/floxCD4Creþ / mice developed
BCC (Supplementary Table S2 online). As in this experiment
BCC were already detectable after 20 weeks of DMBA/TPA
treatment, this time frame seems to suffice for BCC
development. When the skin was stained using an
anti-GFP antibody, single GFPþ cells were detected in the
epidermal and dermal layers as expected (Supplementary
Figure S9a–c online). However, the tumor mass never stained
positive for GFP (Supplementary Figure 9a–c online) but was
strongly positive for Hh signaling activity, as revealed by Gli1
in situ hybridization (Supplementary Figure S9d and e online).
In summary, this experiment also confirms our conclusion
that the BCC in DMBA/TPA-treated Ptchflox/floxCD4Creþ /
mice are not derived from the hematopoietic lineage but from
another CD4Cre-expressing specific cell of the epidermal
layer of the skin.
Identification of a nonhematopoietic CD4-positive cell lineage of
the murine skin
As our data suggested that BCC of DMBA/TPA-treated Ptchflox/
floxCD4Creþ /mice are derived from a specific, nonhemato-
poietic CD4þ epidermal cell, we tried to identify and isolate
such a cell lineage from the murine epidermis. For this
purpose, we isolated keratinocytes from the back skin of
Ptchflox/flox mice by a thermolysin-based method that allows
the detection of trypsin-sensitive antigens such as CD4 by flow
cytometric analyses (Lynch et al., 2003; Jensen et al., 2010).
On the basis of stainings with antibodies against the
keratinocytic marker CD49f (Integrin a 6) and the stem cell
markers Sca1 and CD34, keratinocytes can be divided into
different stem cell populations by flow cytometry (Jensen
et al., 2010; Supplementary Figure S10 online). According to
Jensen et al. (2010), CD49f is highly expressed on hair follicle
stem cells (CD34þ ) and cells of the junctional zone (CD34
Sca1low), whereas suprabasal hair follicle stem cells (CD34þ )
and cells of the isthmus (CD34 Sca1low) are characterized by
low CD49f expression levels. CD34 Sca1high interfollicular
epidermal cells and cells of the infundibulum are found in
CD49fhigh and CD49flow populations.
By including an anti-CD4 antibody in the staining proce-
dure, we first divided the cells into two populations, a CD4-
negative (CD4 ) and a CD4-positive (CD4þ ) population
(Figure 4a). Subsequently, the CD4 and CD4þ keratinocytes
were analyzed for CD34 and CD49f expression (Figure 4b). In
both fractions, CD49flow and CD49fhigh cells were found
(Figure 4b, fraction I and II). Next, the CD49flow and CD49fhigh
fractions were divided according to the expression of CD34
and Sca1 (Figure 4b). This revealed that the major part of
CD49fhigh CD34þ Sca1 hair follicle stem cells and
CD49flow CD34þ Sca1 suprabasal hair follicle stem cells
were found in the CD4 fraction. Interestingly, the analysis
led to the identification of a CD34intermediate Sca1þ keratino-
cyte subpopulation in the CD4þ CD49fhigh cell fraction
(Figure 4b). This population was not detected in the CD4þ
CD49flow fraction (see overlays in Figure 4). This, to our
knowledge previously unreported, CD4þ cell population of
the skin is not comparable with any other subpopulation,
which can be identified by anti-CD49f, anti-CD34, and anti-
Sca1 antibody stainings (see overlay Figure 4b and
Supplementary Figure S10 online). In contrast to this CD4þ
CD49fhigh CD34intermediate Scaþ , the CD4-expressing lympho-
cyte fraction (see side scatter cytometry/forward scatter cyto-
metry in Figure 4b) neither expresses CD49f, CD34 nor Sca1
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Figure 4. Flow cytometric analysis of keratinocytes isolated from the back skin of Ptchflox/flox mice. Keratinocytes of the back skin of Ptchflox/flox mice were isolated
and stained with anti-CD4, anti-CD49f, anti-CD34, and anti-Sca1 antibodies, as described in the Materials and Methods section. (a) Cells were divided into a CD4-
negative and a CD-positive fraction. (b) On the basis of SSC/FSC, keratinocytes and lymphocyte fractions were distinguished and were separately divided into
CD49fhigh (I) and CD49flow (II) fractions. Subsequently, these fractions were analyzed for CD34 and Sca1 expression (Jensen et al., 2010) (for analysis of the
lymphocyte fraction see Supplementary Figure S11 online). The overlays of the CD34/Sca1 plots of the CD4þ and the CD4 fractions revealed a CD4þ CD49fhigh
Scaþ cell population (0.23% of all keratinocytes) that expresses intermediate levels of CD34. FSC, forward scatter cytometry; SSC, side scatter cytometry.
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(Supplementary Figure S11 online), indicating that the isolated
CD4þ stem cell fraction of the skin is a nonhematopoietic
population.
DISCUSSION
BCC development is closely linked to the activation status of
the Hh signaling pathway because of mutations in the Hh
receptor Ptch. For example, germline mutations of PTCH in
humans result in basal cell nevus syndrome that confers a
marked susceptibility to developing BCC. PTCH mutations are
also found in up to 90% of sporadic human BCC (Epstein,
2008). Similarly, it has been shown that Ptch also functions as
a ‘gate keeper’ for BCC development in mice (Adolphe et al.,
2006). Whereas there is no doubt that PTCH mutations are a
very early event during BCC development, the questions about
secondary hits necessary for tumor promotion and expansion
of the initiated cells remain unresolved.
Our data presented here show that mice with a conditional
loss of Ptch in specific epidermal cells develop BCC. Further-
more the formation of BCC strictly depends on a biallelic
mutation of Ptch in the initiated cell and on a subsequent
DMBA/TPA treatment. This conclusion is based on the fact that
the BCC strongly express Gli1 and mutant Ptch (Figure 1c
and f) but no wt Ptch transcripts (Figure 1e). Similar observa-
tions were made in other Ptch-related BCC models (Aszterbaum
et al., 1999; Adolphe et al., 2006; Nitzki et al., 2010). This
shows that aberrant Hh signaling activity as measured by Gli1
overexpression is central for BCC development (Nilsson et al.,
2000; Adolphe et al., 2006). Moreover, our data demonstrate
that the activation of Hh signaling due to Ptch loss is specific for
BCC and has not been detected in papillomas that also
develop after treatment with DMBA/TPA (Figures 1 and 3;
Supplementary Figure S3 and S9 online; and Kang et al., 2013).
This shows that biallelic loss of Ptch and thus active Hh
signaling activity is required for BCC formation but not for
papilloma development (Kang et al., 2013).
BCC formation in Ptchflox/floxCD4Creþ /mice also requires
a DMBA/TPA treatment. This two-step carcinogenesis protocol
consists of a single treatment with DMBA, which is a strong
carcinogen that leads to the formation of DNA adducts
(RamaKrishna et al., 1992) and thus to genotoxicity and
mutations. The subsequent treatment with TPA leads to
tumor promotion by changing the epidermal homeostasis,
which is thought to be necessary for the clonal expansion of
an initiated cell (Yuspa, 1998). The ‘classic’ DMBA/TPA-
induced skin lesions are premalignant papilloma and
squamous cell carcinoma. The stages of experimental mouse
skin carcinogenesis likely starts with DMBA-induced Hras
G61L mutations (Balmain et al., 1984; Quintanilla et al.,
1986; Kemp et al., 1993; Yuspa, 1998) and the development
of papilloma. A consecutive mutation in p53, together with
the biallelic Hras mutation, finally results in malignant
conversion characterized by TPA-induced activation of the
EGFR signaling, followed by the activation of protein kinase C
(Yuspa, 1998; Barbosa et al., 2003). The latter processes cause
alterations in keratinocyte cell cycle progression, terminal
differentiation, and migration (Yuspa, 1998). As DMBA/TPA-
induced BCC neither showed active Ras signaling nor the Hras
G61L mutation (see Figure 2), which is commonly found in
DMBA-induced papilloma (Figure 3; Quintanilla et al., 1986;
Kemp et al., 1993), DMBA/TPA-induced BCC formation in
Ptchflox/floxCD4Creþ /mice follows a molecular mechanism
different from papilloma formation. Although BCC formation
is clearly associated with aberrant Hh signaling activity, it
recently has been demonstrated that BCC-initiating cells exist
that are resistant to Hh-inhibiting agents (Colmont et al.,
2013). This shows that besides members of Hh signaling,
other genes that might be targets of mutagenic agents such as
DMBA are involved in the expansion of the BCC-initiating
cells. One example is CD200, which is expressed by hair
follicle bulge stem cells and which has been shown to be
important for BCC initiation (Colmont et al., 2013). Another
example is Igfbp2 (IGF-binding protein 2), which is a key
mediator of the expansion of epidermal stem/progenitor cells
in BCC and is regulated by Ptch (Villani et al., 2010). As TPA
is a known activator of Igfbp2 expression (Hakeda et al., 1994;
Chambery et al., 2000), one could speculate that the
expansion of Ptch mutant tumor-initiating cells of Ptchflox/flox
CD4Creþ /mice is further promoted by an upregulation of
Igfbp2 on DMBA/TPA treatment, whereas the cells do not
expand in the absence of the drugs. However, unfortunately
we have not analyzed the effects of DMBA or TPA alone
on skin carcinogenesis in Ptchflox/floxCD4Creþ / mice.
Therefore, the exact mechanism of BCC development in
these mice upon DMBA/TPA treatment remains unresolved.
In our studies, we furthermore addressed the question about
the cellular origin of the BCC in Ptchflox/floxCD4Creþ / mice.
Because the CD4Cre recombinase efficiently targets CD4-
expressing cells (Wolfer et al., 2001), it is tempting to
speculate that the BCC in Ptchflox/floxCD4Creþ / mice
originate from a certain CD4-expressing T cell or a related
CD4-expressing BM-derived precursor. Indeed, peripheral
blood mononuclear cells have the capacity to
transdifferentiate into epithelial-like cells (Medina et al.,
2007). Furthermore, BM-derived cells have been reported as
transit-amplifying cells at injured skin, where they differentiate
into keratinocytes (Borue et al., 2004). Finally, in patients who
underwent a BM transplantation, donor BM cells that
expressed keratinocyte markers were detectable in the
epidermis and maintained for over 3 years after the
transplantation (Wagner et al., 2010; see also Oyama and
Kaneko, 2011). As CD34þ hematopoietic stem cells can
coexpress CD4 (Muench et al., 1997; Banda et al., 1999), it
is possible that these cells have been mutated in Ptchflox/flox
CD4Creþ / mice and after infiltration of the skin may have
contributed to BCC formation. However, our transplantation
experiments and immunohistological stainings suggest that the
DMBA/TPA-induced BCC are not derived from particular T
cells or BM-derived cells, but from an epidermal cell of the
skin, which expresses CD4 or at least the CD4Cre transgene.
Admittedly, the experiments support, rather than formally
prove, that the BCC are derived from an epidermal cell.
However, we note that the transplantation experiment, in
which we transplanted GFPþ BM into lethally irradiated
Ptchflox/floxCD4Creþ /mice, demonstrated that the BCC are
derived from a specific host cell and not from the GFPþ BM.
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In addition, the fact that Rag2 /cyc / mice, which are
devoid of any T cell (Mazurier et al., 1999), did not
develop BCC when repopulated with Ptchflox/flox
CD4Creþ /or Ptchflox/floxCD4Creþ /R26RT/BM strongly
argues against an origin from BM or T cells. Moreover, the
latter experiment demonstrates that BCC formation in Ptchflox/flox
CD4Creþ / mice is not the result of any potential deficiency in
T-cell function.
Previously, Kasper et al. (2011) showed that a severe skin
damage such as wounding and TPA treatment has a BCC-
promoting effect due to recruitment of tumor-initiating bulge
cells from the neighboring hair follicles. In contrast, BCC in
Ptchflox/floxCD4Creþ / mice do not develop after wounding,
but only occur after DMBA/TPA treatment. As in Ptchflox/flox
CD4Creþ /R26RT/ mice the traced cells (i.e., LacZþ cells)
were found in the basal layer of the epidermis and in
cells of the root sheath (see Supplementary Figure S6
online), we hypothesize that these cells represent stem cells
localized in the respective structures, which can give rise to
BCC as well.
Remarkably, flow cytometric analyses of isolated murine
keratinocytes now uncovered a, to our knowledge previously
unreported, CD4-expressing stem cell-like population of the
skin, which might be the source of DMBA/TPA-induced BCC
in our model. Besides expressing CD4, these candidate cells
express the stem cell markers CD34 and Sca1, which are
known markers of stem cells of the skin (Jensen et al., 2010).
To our best knowledge, CD4-expressing keratinocytes, hair
follicle (stem) cells, or other epidermal cells have never been
described so far. Although it remains to be verified whether
these CD4þ cells are indeed the source of BCC-initiating skin
cells in DMBA/TPA-treated Ptchflox/floxCD4Creþ / mice, their
stem-like character makes them excellent candidates. If this
comes true, this cell population with its unique expression
profile would be different from any other known sources of
BCC development such as hair follicle stem cells (Youssef
et al., 2010; Kasper et al., 2011; Wang et al., 2011; Wong and
Reiter, 2011). Finally, the discovery of this cell population also
makes it unlikely that BCC in Ptchflox/floxCD4Creþ / mice
developed owing to a ‘leaky’ activation of the CD4Cre
minigene in CD4-negative epidermal cells.
Together, our data suggest that BCC in Ptchflox/flox
CD4Creþ / mice are potentially derived from CD4þ stem
cells of the skin. In addition, the data implicate that the
biallelic loss of Ptch in these specific precursor cells is not
sufficient for BCC formation and requires a second hit such as
DMBA/TPA treatment, which results in the expansion of the
Ptch mutant cells.
MATERIALS AND METHODS
Compounds
DMBA (7,12-dimethylbenz(a)anthracene) and TPA (12-O-tetradeca-
noylphorbol-13-acetate) were obtained from Sigma-Aldrich, Munich,
Germany and were dissolved in acetone.
Animals
All experiments using animals were performed in compliance with all
legal and ethical requirements. CD4Creþ / mice were on a C57BL/6
(B6) genetic background (Wolfer et al., 2001). Ptchflox/flox mice on a
[(R1B6)B6] genetic background (Zibat et al., 2009; Uhmann
et al., 2011) were intercrossed and bred to CD4Creþ / mice
to obtain Ptchflox/floxCD4Creþ / mice. Characterization and geno-
typing of Ptchflox/floxCD4Creþ / mice were conducted as described
previously (Uhmann et al., 2011). In addition, Ptchflox/floxCD4creþ /
mice were crossed to R26R animals (B6 genetic background; Soriano,
1999), resulting in Ptchflox/floxCD4Creþ /R26RT/ mice. In the latter
mouse strain, all CD4-expressing cells are marked by the permanent
expression of LacZ.
The transgenic EGFP-expressing mouse line TgN(beta-act-EGFP) on
B6 genetic background was maintained and genotyped as described by
Okabe et al. (1997). Rag2 / cyc / mice on B6 genetic background
were purchased from Taconic (Germantown, New York, NY).
DMBA/TPA treatment of mice
The right flank of 8-week-old mice was shaved using an electrical hair
clipper 2 days before a single topical application of 200 nM DMBA
(dissolved in 200ml acetone). One week after DMBA application,
20 nM TPA (in 50ml acetone) was applied topically twice a week for
20, 26, or 34 weeks, as indicated in Supplementary Table S1 online.
The treated skin area was shaved regularly, and the number of tumors
per mouse was recorded twice weekly. Animals were killed after the
last TPA treatment, and the treated skin areas were preserved for
further analyses.
Other methods
Isolation of keratinocytes and flow cytometric analysis, incision
wounding, adoptive transfer experiments, LacZ staining of skin
samples, microdissection, and RFLP analysis of Hras exon 2 were
adopted from Wu and Morris (2005) and Jensen et al. (2010), Kasper
et al. (2011), Uhmann et al. (2007) and Uhmann et al. (2011),
Dittmann et al. (2013), Junker et al. (2009), and Nagase et al. (2003),
respectively. Histopathology, immunohistochemistry, and in situ
hybridization were performed as described in Nitzki et al. (2010).
More details are given in the Supplementary Methods section.
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